Fat Loss Peptide Stack (MOTS-C + AOD-9604 + Tesofensine)
This fat loss peptide stack combines MOTS-C, AOD-9604, and tesofensine for metabolic support, appetite control, and body recomposition research. The title intentionally includes the peptide names because there are multiple similarly named fat-loss stacks in the broader library.
Fat Loss Peptide Stack Quick Overview
| Peptide | Purpose | Typical Dose |
|---|---|---|
| MOTS-C | Metabolic support | 10 mg 3x/week |
| AOD-9604 | Fat metabolism support | 300 mcg daily |
| Tesofensine | Appetite control | 0.25–0.5 mg daily |
What Is the Fat Loss Peptide Stack
This stack is built around three different roles: MOTS-C for metabolic flexibility and energy-related signaling, AOD-9604 for fat-mobilization research, and tesofensine for appetite-related support. It is not the only “fat loss stack” in the library, so the page title is written with exact ingredients to avoid ambiguity.
In practice, people look at this stack when they want a combination of body-composition support and adherence support. Human data for the exact combination is limited, so the stack is best viewed as a protocol concept assembled from individual compounds rather than a clinically validated bundle.
How the Stack Works
MOTS-C
- Metabolic signaling — is studied for insulin sensitivity and energy regulation
- Exercise synergy — may interact with training and AMPK-related pathways
- Body recomposition interest — is commonly discussed for metabolic flexibility rather than simple scale loss
AOD-9604
- Lipolysis interest — is discussed for fat-breakdown signaling
- Body-fat targeting — was developed to focus on fat metabolism rather than broad GH effects
- Morning use pattern — is often paired with fasted or early-day protocols
Tesofensine
- Appetite suppression — is commonly discussed for reduced calorie intake
- Adherence support — may help people stay more consistent with a deficit
- Weight-management role — is often included when hunger is the main bottleneck
Together, this stack aims to cover metabolism, fat mobilization, and appetite. That makes it different from simpler fat-loss stacks that rely on just one metabolic peptide or only an appetite-focused compound.
Benefits
- Metabolic support and body recomposition focus
- Appetite-control support
- Exercise-friendly energy positioning
- Fat-loss stack differentiation by exact ingredients
- Potential synergy between metabolic and adherence goals
Typical Protocol
| Week | MOTS-C | AOD-9604 | Tesofensine |
|---|---|---|---|
| 1–4 | 10 mg 3x/week | 300 mcg daily | 0.25 mg daily |
| 5–8 | 10 mg 3x/week | 300 mcg daily | 0.25–0.5 mg daily |
A common structure is 4–8 weeks with appetite support adjusted more conservatively than the peptide components. For more on the metabolic side of the stack, see the MOTS-C results timeline.
Results Timeline
- Week 1–2: Appetite and energy changes are the earliest effects many people look for
- Week 3–4: Adherence, training consistency, and early body-composition changes become the focus
- Week 5–8: Recomposition and metabolic outcomes are typically assessed over a longer window
Outcomes depend heavily on diet, training, sleep, and tolerability. For peptide-specific context, see the MOTS-C timeline guide.
Stack Calculator
FAQs
What is the fat loss peptide stack?
This version of the fat loss peptide stack combines MOTS-C, AOD-9604, and tesofensine. It is designed to differentiate it from other fat-loss stacks by naming the exact components in the title and content.
Why include tesofensine in this stack?
Tesofensine is typically discussed for appetite suppression and adherence support, while MOTS-C and AOD-9604 are more commonly discussed for metabolic and fat-mobilization goals. Together they create a more appetite-aware stack concept.
How long does a fat loss peptide stack cycle last?
A common pattern is 4–8 weeks depending on the component and whether appetite-support agents are included. Protocols vary widely, so many users start conservatively and reassess tolerance before extending a cycle.
Is this stack only for body weight reduction?
No. It is often discussed more broadly in terms of metabolic support, body recomposition, appetite control, and exercise adherence, not just scale weight alone.
Is there strong human evidence for the full stack?
No. Human evidence for the exact three-part stack is limited. Most support comes from individual compound research and theoretical stacking rather than trials on the full combination.
Sources
- Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss (PubMed)
- MOTS-c interacts synergistically with exercise intervention to regulate PGC-1α expression, attenuate insulin resistance and enhance glucose metabolism in mice via AMPK signaling pathway (PubMed)
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice (PubMed)
- Tesofensine--a novel potent weight loss medicine (PubMed)
Internal linking
Related Peptides
Related Protocols
Related Calculators
Related Stacks
For educational and research purposes only. Not medical advice. Consult a licensed healthcare professional for personal guidance.